ASCO 2013
The American Society of Clinical Oncology (ASCO) is holding its 2013 Annual Meeting in Chicago, IL from May 31-June 4, 2013. "Building Bridges to Conquer Cancer" is the theme of this year's meeting which will bring more than 250,000 oncology professionals together.
Day 1
Early Signs of Promise as Yale's Herbst Details PD-L1 Immunotherapy Data
Results detailed today offer hope that a new form of immunotherapy will propel the bodies of some cancer patients to fight tumors, not be overrun by them, according to a study outlined at the Annual Meeting of the American Society of Clinical Oncologists (ASCO) in Chicago.
Less is More: Researchers Surprised by Radiotherapy Results Involving Locally Advanced NSCLC
Patients in a phase III trial lived longer and experienced fewer treatment-related deaths from locally advanced non-small cell lung cancer (NSCLC) after receiving the standard dose of radiotherapy, compared to those receiving a high dose, according to a study presented today at the Annual Meeting of the American Society of Clinical Oncologists (ASCO).
Symptoms, Not Scans, Offer Better Measure of Relapse for DLBCL Patients
Imaging spotted relapses for just a tiny fraction of patients with diffuse large B-cell lymphoma (DLBCL) before symptoms appeared, according to a new multi-institutional study, prompting recommendations that the radiation exposure of follow-up scans may not be worthwhile for all patients.
Day 2
Long-Term Study Affirms Link Between Cardiovascular Fitness, Lower Cancer Risk in Men
This finding makes it clear that patients should be advised that they need to achieve a certain fitness level, and not just be told that they need to exercise. Unlike patient-reported exercise behavior, Lakoski said, fitness can be objectively and accurately measured in a clinical setting.
Results Show Idelalisib May Offer Option Where Few Exist for CLL Patients
Half the patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who were treated with idelalisib in a phase I study experienced rapid and prolonged tumor shrinkage, a promising finding given the limited treatment choices for this group.
Dr. Andrew Seidman Discusses the Management of Patients With Brain Metastases
Over the 20 years I've been treating breast cancer, I think this is the one area where we've really lagged behind in terms of making progress, said Andrew Seidman, MD, attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY.
Dr. Kolodziej Discusses The Use of Novel Treatments in Combination Therapy
Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, discusses the financial challenges associated with the combination of newer novel agents in breast cancer treatment.
Day 3
Dr. George Talks About New Data on Checkpoint Inhibitors
In this video, Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, shares his thoughts on the most exciting data to be presented on immunotherapies at the ASCO Annual Meeting 2013.
Dr. Kolodziej Addresses the Impact of Payer Policy on the Use of Immunotherapy
Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that in regard to payers impacting the use of immunotherapies, most payers have decided they will respect the judgment of the Food and Drug Administration, Centers for Medicare & Medicaid Services and the National Comprehensive Cancer Network.
In Phase II Study, Combination Therapy Extends Survival, Reduces Side Effects in Metastatic Melanoma Patients
Two-thirds of the metastatic myeloma patients in a phase II study were still alive a year after receiving a new combination therapy, compared to slightly more than half of patients receiving a standard monotherapy for the cancer, according to results presented today at the 49th Annual meeting of the American Society of Clinical Oncology in Chicago.
Phase III Study Finds Kidney-Cancer Drug Prevents Relapses of Ovarian Cancer
Ovarian cancer survivors could have an option for treatment after chemotherapy, based on the outcome of a phase III study of an approved oral therapy for kidney cancer and soft tissue sarcoma.
Day 4
Safety Trial Supports Weekly Dosing of Oral 20S Proteasome Inhibitor in Multiple Myeloma Patients
An ongoing phase I study of patients who have experienced relapsed and/or refractory multiple myeloma has found that this population was largely able to tolerate a new oral 20S proteasome inhibitor after receiving other prior treatments.
Dr. George Addresses Provider Issues Regarding Immunotherapies
Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer.
Dr. Kolodziej Discusses Personalized Medicine in Oncology
Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that the rapid emergence of precision medicine was one of the more interesting topics discussed at the ASCO 2013 Annual Meeting.
Penn Survey Finds Cancer Drug Shortages Affect Treatment, Research
Ongoing shortages of common oncology chemotherapies have compelled physicians to substitute more expensive drugs, delay or suspend clinical trials, or even skip doses of chemotherapy, according to survey results gathered by a team from the University of Pennsylvania.